ArticleJournal of clinical medicine2022
Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Practices of high-flow nasal therapy in acute and chronic respiratory failure: the Hi-Flow Survey.BMJ open respiratory research · 2025Article
- Addressing sputum challenges in bronchiectasis: high-flow therapy as a game-changer for airway clearance care.ERJ open research · 2025Article
- Impact of long-term high-flow nasal therapy on mucus plugs in patients with bronchiectasis.ERJ open research · 2025Article
- Home High-Flow Nasal Cannula in Patients with Chronic Respiratory Failure: A Literature Review and Suggestions for Clinical Practice.Tuberculosis and respiratory diseases · 2025Article
- The impact of different prong-nares ratio on ventilation in COPD patients using nasal high-flow (NHF) - a physiological study.BMC pulmonary medicine · 2024Article
- Long-Term High-Flow Nasal Therapy in Patients with Bronchiectasis of Different Severity: A Retrospective Cohort Study.Journal of clinical medicine · 2024Article
- Patient-managed interventions for adults with bronchiectasis: evidence, challenges and prospects.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Effects of high-flow nasal therapy on swallowing function: a scoping review.ERJ open research · 2024Article
- Effect of Nasal High Flow (NHF) on Right Heart Function in Stable Patients with Pulmonary Hypertension of Different WHO Classes.Journal of clinical medicine · 2024Article
- Effects of High-Flow Nasal Cannula on Right Heart Dysfunction in Patients with Acute-on-Chronic Respiratory Failure and Pulmonary Hypertension.Journal of clinical medicine · 2023Article
- A Real-Life Study of Combined Treatment with Long-Term Non-Invasive Ventilation and High Flow Nasal Cannula in Patients with End-Stage Chronic Obstructive Lung Disease.Journal of clinical medicine · 2023Article
- High-Flow Nasal Therapy in Acute and Chronic Respiratory Failure: Past, Present, and Future.Journal of clinical medicine · 2023Article
- The Danish respiratory society guideline for long-term high flow nasal cannula treatment, with or without supplementary oxygen.European clinical respiratory journal · 2023Article
- New Frontiers in High-Flow Therapy.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-flow nasal therapy (HFNT) provides several pathophysiological benefits in chronic respiratory disorders. We aimed to evaluate the effectiveness of long-term HFNT in patients with bronchiectasis (BE).
methodsThis is a retrospective bicentric case-control study of outpatients with BE on optimized medical treatment with a severe exacerbation requiring hospitalization in the previous year. Patients on long-term home HFNT (cases) and patients on optimized medical treatment alone (controls) were matched by age, sex, bronchiectasis severity index, and exacerbations in the previous year. Data on BE exacerbations, hospitalizations/year, mucus features, respiratory symptoms, and pulmonary function were collected. The primary outcome was the change from baseline in the exacerbation rates at 12 months between groups.
results20 patients in the HFNT group and 20 controls were included. A significant reduction in exacerbations [-1.9 (-2.8 to -0.9),
conclusionsIn this preliminary study, long-term domiciliary HFNT improved the clinical course of patients with BE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.